Last edition
News about "Intas Pharmaceuticals"
NPPA Fixes Retail Prices for 11 Drug Formulations Under DPCO 2013
The National Pharmaceutical Pricing Authority (NPPA) has issued a fresh notification fixing retail prices for multiple essential drug formulations—including antihypertensives, antibiotics, antidiabetics, and paediatric syrups—under the Drugs (Prices Control) Order, 2013. The revised prices apply to approved manufacturers and exclude GST.
Intas Pharmaceuticals | 02/12/2025 | By Dineshwori
Accord BioPharma Launches IMULDOSA Prefilled Syringes at Lowest WAC Price
Accord BioPharma has announced the commercial launch of IMULDOSA (ustekinumab-srlf), a biosimilar to STELARA (ustekinumab).
Intas Pharmaceuticals | 19/08/2025 | By Dineshwori | 216
Intas Pharmaceuticals Acquires UDENYCA from Coherus BioSciences
Intas Pharmaceuticals, along with its global subsidiaries operating under the Accord brand, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, strengthening its global biosimilar portfolio and strengthening its position in the pegfilgrastim market.
Intas Pharmaceuticals | 07/08/2025 | By Mrinmoy Dey | 163
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the world’s first PD-1 inhibitor approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the Indian market.
Intas Pharmaceuticals | 06/08/2025 | By Mrinmoy Dey | 258
Accord BioPharma Signs Exclusive US Licensing Deal with Bio-Thera for BAT2506
BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha).
Intas Pharmaceuticals | 11/02/2025 | By Aishwarya | 567
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy